COLLINSON
27.6.2024 10:01:32 CEST | Business Wire | Press release
Collinson, a global leader in travel experience and loyalty programmes, has announced a strategic partnership with World Nomads, the global travel insurance provider, including the launch of a new Annual Multi-Trip (AMT) product in the UK & Ireland.
The new product range will enhance the customer experience with the addition of increased coverage limits and new benefits that apply to both annual and single-trip policies, as well as innovative parametric service, SmartDelayTM. These enhancements ensure that travellers are better protected against a wider range of travel-related issues and unexpected flight delays or cancellations.
As part of the partnership, Collinson will be responsible for underwriting the AMT product as well as providing World Nomad customers with the use of its new parametric product SmartDelay.
SmartDelay is a real-time, parametric product which provides customers with a range of benefits in the event of a flight disruption, for example, providing access to over 1500 airport lounges or alternative benefits such as spa, sleep pods and restaurant discounts for travellers experiencing flight delays. SmartDelay also gives traveller access to Air Doctor, which connects travellers with private doctors and medical advice in destinations where public health services may be overstretched and/or unable to treat international travellers.
This new partnership supports Collinson’s UK and European growth ambitions, allowing the company to underwrite business for World Nomads in the UK, Ireland, Germany, Denmark, Belgium and Holland, with more to follow.
Greg Lawson, Head of Travel Insurance at Collinson, said: “Given both Collinson and World Nomads are established and respected brands by travellers globally, our collaboration in developing products that deliver above and beyond what today’s travellers demand from their travel insurance, demonstrates our commitment in offering fair value, flexibility and choice. The synergies of our companies make our partnership stronger, given Collinson’s experience as a renowned travel underwriter and World Nomad’s commitment to offer innovative travel insurance. It’s a great time to bring exciting products to the travel market to drive our shared UK and European growth ambitions.”
World Nomads’ AMT policy offers comprehensive and cost-effective coverage for frequent international and domestic travellers, allowing for multiple trips within a one-year period under a single policy. Additionally, a higher age limit (up to 69 years) and free coverage for children (aged under 18) when travelling with adult relatives or friends applies, making the AMT policy ideal for multigenerational travel.
Jonathan Frankham, General Manager, UK and Europe, World Nomad, said: “Both the introduction of the AMT product and the integration of Collinson as World Nomads’ new underwriters reflect our unwavering commitment to providing adventurous travellers with the most comprehensive and innovative coverage available. We are thrilled to offer an enhanced travel insurance experience that addresses the unique needs of today's travellers. With features like Air Doctor and SmartDelay, our travellers can tackle today's most common travel challenges with confidence, enjoying seamless access to medical care and luxurious airport lounges during delays.”
Issued by Rein4ce on behalf of Collinson
About Collinson
Collinson Insurance: specialty lines, travel and accident & health insurance, includes underwriting capacity, insurance products and access to expert TPAs in the UK and Europe. Our deep understanding of loyalty and membership programmes enables us to offer true differentiation, so clients have confidence in our partnership to deliver growth. SmartDelay is a parametric service that ensures airline passengers who have registered their flight are given access to an airport lounge or alternative benefit, in the event of a flight delay or cancellation. Priority Pass is the world’s original and market-leading airport experiences programme. We provide travellers with access to over 1,500 airport lounges and travel experiences in over 700 airports in 145 countries.
About World Nomads
World Nomads is a fast-growing, global travel insurance company. We provide inspirational stories, safety tips and specialised travel insurance for adventurous and independent travellers. Our online travel insurance offers cover to travellers from more than 100 countries and allows you to buy and claim online, 24/7, even while already traveling.
Our travel insurance focuses on what we believe is important to travellers: emergency medical and evacuation costs, baggage, trip cancellation, trip delay and trip interruption costs. We also offer cover for more than 200 adventure sports and activities, plus tech and gear. Our policies are underwritten by a suite of specialist travel insurers that provide 24/7 emergency assistance, customer service and claims support, making us a top choice for many of the world's leading adventure, independent and youth travel brands.
World Nomads is a part of the nib Group which provides health and medical insurance to more than 1.5 million Australian and New Zealand residents. We also provide health insurance to more than 170,000 international students and workers in Australia and are Australia’s third-largest travel insurer and global distributor of travel insurance through our business nib Travel.
https://www.worldnomads.com/uk/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627952877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom